20 Participants Needed

Fecal Microbiota Transplantation for Colitis

SK
Overseen BySuchitra K Hourigan, M.D.
Age: < 65
Sex: Any
Trial Phase: Phase 1 & 2
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 2 JurisdictionsThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial is testing if placing healthy bacteria from donor stool into the intestines of people with CGD and colitis can reduce inflammation. The target group is patients aged 10-60 who haven't responded to other treatments. The goal is to restore a healthy balance of gut bacteria to reduce inflammation. This method has shown promise in treating inflammatory bowel diseases like ulcerative colitis by restoring a healthy gut balance.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but it requires that there be no planned changes in your systemic antibiotic regimen for CGD or escalation in CGD-IBD treatment for 1 month before the FMT. If you are taking monoclonal antibodies for CGD-IBD, the dose must be stable for 12 weeks with no planned increase.

Is fecal microbiota transplantation (FMT) safe for humans?

FMT has been used to treat various gastrointestinal conditions, and while it shows promise, the safety data is still limited. Short-term side effects can occur, and long-term safety is not well understood yet, but ongoing research aims to improve safety and tolerability.12345

How is fecal microbiota transplantation different from other treatments for colitis?

Fecal microbiota transplantation (FMT) is unique because it involves transferring stool from a healthy donor to a patient to restore healthy gut bacteria, unlike traditional medications that target symptoms or inflammation directly. This treatment can be administered through colonoscopy, enemas, or potentially oral capsules, and aims to increase microbial diversity in the gut, which may help induce remission in ulcerative colitis.14678

What data supports the effectiveness of the treatment Fecal Microbiota Transplantation for Colitis?

Research shows that fecal microbiota transplantation (FMT) can be effective for treating ulcerative colitis, a type of inflammatory bowel disease. Studies indicate that FMT can increase beneficial bacteria in the gut and help induce remission in patients who haven't responded to other treatments.356910

Who Is on the Research Team?

SK

Suchitra K Hourigan, M.D.

Principal Investigator

National Institute of Allergy and Infectious Diseases (NIAID)

Are You a Good Fit for This Trial?

This trial is for people aged 10-60 with Chronic Granulomatous Disease (CGD) and colitis who haven't responded well to other treatments. They must have a specific level of inflammation marker in their stool, no recent changes in antibiotics or escalation in CGD treatment, and if they can get pregnant, agree to use effective contraception.

Inclusion Criteria

HBI score >=5 (to be evaluated on Day 1)
I've been on a stable dose of monoclonal antibodies for my condition for 12 weeks.
I am over 18 and can consent, or if under 18, my guardian can.
See 6 more

Exclusion Criteria

Any condition that, in the opinion of the investigator, contraindicates participation in this study
Pregnant or breastfeeding
I have had complications from inflammatory bowel disease, like fistulas or abscesses.
See 8 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks
1 visit (telehealth)

Treatment

Participants receive fecal microbiota transplantation (FMT) delivered by colonoscopy

3-5 days
Inpatient stay at NIH hospital

Follow-up

Participants are monitored for safety and effectiveness after treatment

6 months
9 visits (telehealth), up to 2 visits (in-person)

What Are the Treatments Tested in This Trial?

Interventions

  • OpenBiome FMT product FMP250
Trial Overview The trial tests whether transplanting good bacteria from donor stool into the intestines (Fecal Microbiota Transplantation - FMT) can reduce colon inflammation in CGD patients. Participants will undergo various tests including a colonoscopy to deliver the FMT material and follow-up telehealth visits over 6 months.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: InterventionalExperimental Treatment1 Intervention

OpenBiome FMT product FMP250 is already approved in United States, European Union for the following indications:

๐Ÿ‡บ๐Ÿ‡ธ
Approved in United States as OpenBiome FMT product FMP250 for:
๐Ÿ‡ช๐Ÿ‡บ
Approved in European Union as OpenBiome FMT product FMP250 for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

National Institute of Allergy and Infectious Diseases (NIAID)

Lead Sponsor

Trials
3,361
Recruited
5,516,000+

Published Research Related to This Trial

In a study of 30 patients with ulcerative colitis who did not respond to standard treatments, 70% showed a clinical response to fecal microbial transplantation (FMT) after 12 weeks, with 43.3% achieving both clinical and endoscopic remission.
FMT was found to be a safe alternative to immunosuppressive therapies, with only mild adverse events reported in 23.3% of patients, suggesting it could be a promising option for those with refractory ulcerative colitis.
Fecal microbiota transplantation is a rescue treatment modality for refractory ulcerative colitis.Uygun, A., Ozturk, K., Demirci, H., et al.[2018]
In a pilot study of 20 patients with active ulcerative colitis, 35% achieved a clinical response and 15% reached remission after a single fecal microbiota transplantation (FMT) using a high-diversity, 2-donor fecal microbiota preparation, indicating its potential efficacy.
The study found that FMT significantly increased the diversity of the gut microbiome in patients, and the composition of the donor microbiota was linked to clinical outcomes, suggesting that donor selection may play a crucial role in treatment success.
Single Delivery of High-Diversity Fecal Microbiota Preparation by Colonoscopy Is Safe and Effective in Increasing Microbial Diversity in Active Ulcerative Colitis.Jacob, V., Crawford, C., Cohen-Mekelburg, S., et al.[2022]
The study demonstrated that daily oral administration of frozen encapsulated fecal microbiota transplantation (cFMT) is safe and well-tolerated in patients with mild to moderate ulcerative colitis (UC), with no treatment-related adverse events reported.
Two out of six subjects receiving cFMT achieved clinical remission, suggesting that cFMT may help maintain beneficial changes in gut microbiota and improve clinical outcomes, although further research is needed to confirm these findings and address home storage issues.
Daily, oral FMT for long-term maintenance therapy in ulcerative colitis: results of a single-center, prospective, randomized pilot study.Crothers, JW., Chu, ND., Nguyen, LTT., et al.[2022]

Citations

Fecal microbiota transplantation is a rescue treatment modality for refractory ulcerative colitis. [2018]
Single Delivery of High-Diversity Fecal Microbiota Preparation by Colonoscopy Is Safe and Effective in Increasing Microbial Diversity in Active Ulcerative Colitis. [2022]
Daily, oral FMT for long-term maintenance therapy in ulcerative colitis: results of a single-center, prospective, randomized pilot study. [2022]
Relief of irritable bowel syndrome by fecal microbiota transplantation is associated with changes in diversity and composition of the gut microbiota. [2020]
Fecal Microbiota Transplantation for the Treatment of Ulcerative Colitis: A Qualitative Assessment of Patient Perceptions and Experiences. [2022]
Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial. [2022]
[Current research progress and thinking of fecal microbiota transplantation for the treatment of gastrointestinal disorders]. [2020]
[A pilot study of treating ulcerative colitis with fecal microbiota transplantation]. [2022]
A single faecal microbiota transplantation modulates the microbiome and improves clinical manifestations in a rat model of colitis. [2020]
[Patient perception and approval of fecal microbiota transplantation (FMT) as an alternative treatment option for ulcerative colitis]. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of ServiceยทPrivacy PolicyยทCookiesยทSecurity